Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting;Recomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciario

Gastroenterologia y Hepatologia

Volumn 29, Issue 9, 2006, Pages 551-559

  Saiz De La Hoya Zamácola, Pablo ^a,e   Marco Mouriño, Andrés ^b   Clemente Ricote, Gerardo ^c   Portilla Sogorb, Joaquín ^d   Boix Martínez, Vicente ^d   Núñez Martínez, Óscar ^c   Reus Bañuls, Sergio ^d   Teixidó I Pérez, Nuria ^b  

^a Centro Penitenciario Alicante I   (Spain)

^b Centro Penitenciario de Mujeres   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e Centro Penitenciario de Alicante I   (Spain)

Author keywords

Hepatitis C; HIV infection; Inmates; Prisons

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; DIAGNOSTIC PROCEDURE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREVALENCE; PRISONER; SPAIN; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

EID: 33845439000     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13094351     Document Type: Article

References (93)

1. Grupo del Noroeste para el estudio de la hepatitis por virus C en el medio penitenciario. Seroprevalencia de infección por virus C de la hepatitis en población reclusa del noroeste de España a su ingreso en prisión. Rev Esp Salud Pública. 1998; 72:43-51.
2. Añon C, Del Olmo JA, Llovet F, Serra MA, Gilabert S, Rodríguez F, et al. Virus C de la hepatitis entre población penitenciaria de Valencia. Rev Esp Enferm Dig. 1995;87:505-8.
3. Pérez-Agudo F, Alonso Moreno FJ, Urbina Torija J. Prevalencia de infección por el virus de la inmunodeficiencia humana tipo 1 y de Mycobacterium tuberculosis en una población reclusa entre los años 1989 y 1995. Med Clin (Barc). 1998;110: 167-70.
4. Saiz de la Hoya P, Bedia M, Murcia J, Cebriá J, Sánchez-Payá J, Portilla J. Factores predictivos de infección por el VIH, VHC y coinfección en la población reclusa de una prisión española. Enferm Infecc Microbiol Clin. 2005; 23:53-7.
5. Pallás JR, Farinas-Álvarez C, Prieto D, Delgado-Rodríguez M. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol. 1999;15:699-704.
6. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology. 2002;36: S220-S5.
7. Portilla J, Esteban J, Llinares R, Belda J, Sánchez-Payá J, Manso MI y grupo de estudio protocolo INH. Prevalencia de infecciones crónicas ocultas en una cohorte de pacientes en tratamiento sustitutivo con metadona. Med Clin (Barc). 2001;116: 330-2.
8. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36:210-9.
9. National Institutes of Health Consensus Statement on Management of Hepatitis C: 2002. Gastroenterology. 2002;123: 2082-99.
10. Saiz de la Hoya P, Ortega E y Grupo de Trabajo SESP/GESIDA sobre protocolos de coordinación. Protocolos de Coordinación entre Servicios Sanitarios Penitenciarios y Hospitales de Referencia. Madrid: SCM; 2004.
11. Marco A, Lonca A, Laliga A. Estrategias para el manejo de la infección por el virus de la hepatitis C. Rev Esp Sanid Penit. 2002;4:58-69.
12. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-5.
13. Wawrzynowicz-Syczewska M, Kubicka J, Lewandowski Z, Boron-Kaczmarska A, Radkowski M. Natural history of acute symptomatic hepatitis type C. Infection. 2004;32:138-43.
14. Forns X, Ampurdanés S, Llovet JM, Aponte J, Quinto L, Martínez-Bauer E, et at. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986-92.
15. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. The Multivrc Group. Hepatology. 1999;30:1054-8.
16. Martínez-Sierra C, Arizcorreta A, Díaz F, Roldán R, Martín-Herrera L, Pérez-Guzmán E, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis. 2003;36:491-8.
17. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA. 1998;280:2088-93.
18. Spinzi G, Minoli G. To biopsy or not to biopsy. Hepatology. 2001;34:438.
19. Andriulli A, Mangia A, Niro G, Caturelli E. To biopsy or not to biopsy. Hepatology. 2001;34:438.
20. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002;36 Suppl:152-60.
21. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology. 2004;39:1239-47.
22. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Multivirc Group Lancet. 2001;357:1069-75.
23. Myers RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T. Multivirc Group. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci. 2003;48:146-53.
24. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-26.
25. Rossi E, Adams L, Prins A, Bulsara M, De Boer B, Garas G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem. 2003; 49:450-4.
26. Kaul V, Friedenberg FK, Braitman LE, Anis U, Zaeri N, Fazili J, et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol. 2002; 97:2623-8.
27. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS. 2003;17:721-5.
28. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology. 2004;127:1704-13.
29. Puoti C, Castellacci R, Montagnese F, Zaltron S, Stornaiuolo G, Bergami M, et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminostransfe rase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol. 2002;37:117-23.
30. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology. 2002;36 Suppl 5: 79-84.
31. Zeuzem S, Diago M, Gane E, Reddy R, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004;127:1724-32.
32. Boyacioglu S, Gur G, Yilmaz U, Korkmaz M, Demirhan B, Bilezikci B, et al. Investigation of possible clinical and laboratory predictors of liver fibrosis in hemodialysis patients infected with hepatitis C virus. Transplant Proc. 2004;36:50-2.
33. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol. 2005;5: 615-24.
34. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343-50.
35. Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, et al. Care of patients with hepatitis C and HIV co-infection. AIDS. 2004;18:1-12.
36. Soriano V, Miró JM, García-Samaniego J, Torre-Cisneros J, Núñez M, Del Romero J, et al. Consensus conference on chronic viral hepatitis and HIV infection: update Spanish recommendations. J Viral Hepat. 2004;11:2-17.
37. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39: 1147-71.
38. EASL, International Consensus Conference on Hepatitis C. Consensus statement. J Hepatol. 1999;30:956-61.
39. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358:958-65.
40. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975-82.
41. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140:346-55.
42. Mangia A, Santoro R, Minerva N, Ricci GL, Carrela V, Persico M, et al. Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352: 2609-17.
43. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sánchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40: 993-9.
44. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med. 2002;137: 961-4.
45. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137: 1-10.
46. Kim CH, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328: 983.
47. Takeshi O, Makiyama A, Nakayama M, Sumida Y, Mitsuyoshi H, Nakajima T, et al. A Follow-up study to determine the value of liver biopsy an need for antiviral therapy for hepatitis c virus carriers with persistently normal serum aminotransferase. J Hepatol. 2005;43:599-605.
48. Almasio PL. Weight-based dosing: which impact on efficacy and safety of therapy? Dig Liver Dis. 2004;36:349-53.
49. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med. 2001;345:215-7.
50. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288-92.
51. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 2001;61:211-5.
52. Robaeys G, Mathei C, Buntinx F, Vanranst M. Management of hepatitis C virus infections in intravenous drug users. Acta Gastroenterol BeIg. 2002;65: 99-100.
53. Mehta SH, Cox A, Hoover DR, Wang XH, Mao W, Ray S, et al. Protection against persistence of hepatitis C. Lancet. 2002; 359:1478-83.
54. Backmund M, Meyer K, Von Zielonka, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34:188-93.
55. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 2002;67: 117-23.
56. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-92.
57. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-32.
58. Grando-Lemaire V, Goisset P, Sorge F, Trinchet JC, Castera L, Roulot D, et al. Prise en charge de l'infection par le virus de l'hépatite C dans une population de toxicomanes suivis dans un centre spécialisé ambulatoire. Faisabilité et résultats. Gastroenterol Clin Biol. 2002;26:1091-6.
59. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol. 2003;98:2281-8.
60. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37: 443-51.
61. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology. 2004;40:120-4.
62. Spaulding A, Greene C, Davidson K, Schneidermann M, Rich J. Hepatitis C in state correctional facilities. Prev Med. 1999; 28:92-100.
63. Saiz de la Hoya P, Viciana P, et al. CAPRI. Calidad Asistencial en Prisiones. Documento de consenso. Ed. SCM. Madrid 2002. Disponible en: http://www.sesp.es/sesp/capri/index.html
64. Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses correctional settings. MMWR 2003;52(No. RR-1): 1-33. Disponible en: www. cdc.gov/mmwr/preview/mmwrhtml/rr5201a1.htm
65. Federal Bureau of prisons clinical practice guidelines for the prevention and treatment of viral hepatitis. February 2003. Disponible en: www.hcvinprison.org.
66. Sterling RK, Hofmann CM, Luketic VA, Sanyal AJ, Contos MJ, Mills SA, et al. Treatment of chronic hepatitis C virus in the Virginia Department of Corrections: can compliance overcome racial differences to response? Am J Gastroenterol. 2004; 99:866-72.
67. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138:187-90.
68. Bernstein D. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2004;140:50-1.
69. Hammett TM. Adopting more systematic approaches to hepatitis C treatment in correctional facilities. Ann Intern Med. 2003; 138:235-6.
70. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut. 2003;52:1500-4.
71. Soto B, Sánchez-Quijano A, Rodrigo L, Del Olmo JA, García-Bengoechea M, Hernández-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26: 1-5.
72. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet. 1997;350:1425-31.
73. Monga HK, Rodríguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Vélez M, et al. Hepatitis C infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33:240-7.
74. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-7.
75. Salmon-Ceron D, Lewden Ch, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799-805.
76. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362:1708-13.
77. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001;34: 283-7.
78. Macias J, Castellano V, Merchante N, Palacios RB, Mira JA, Saez C, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS. 2004;18:767-74.
79. Torriani FJ, Rodríguez-Torres M, Rockstroh JK, Lissen E, González García J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-patients. N Engl J Med. 2004;351:438-50.
80. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs interferon alfa-2b plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292: 2839-48.
81. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004; 351:451-9.
82. Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27-F36.
83. Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis. 2003;188:1498-507.
84. Sherman KE, Shire NJ, Rouster SD, Peters MG, James Koziel M, Chung RT, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology. 2005;128:313-27.
85. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol. 1999;30:783-7.
86. Moreno A, Quereda C, Moreno L, Pérez-Elías MJ, Muriel A, Casado JL, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther. 2004;9:133-8.
87. Lafeuillade A, Hittinger G, Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001;357:280-1.
88. Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS. 2004;18:F21-F5.
89. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-6.
90. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology. 2000;31:1207-11.
91. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711-9.
92. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:237-44.
93. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123: 1061-9.